Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

GlobeNewswire August 26, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

GlobeNewswire August 13, 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire August 12, 2024

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

GlobeNewswire August 5, 2024

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire July 19, 2024

Daré Bioscience Announces Reverse Stock Split

GlobeNewswire June 27, 2024

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

GlobeNewswire June 24, 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire May 14, 2024

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

GlobeNewswire May 7, 2024

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

GlobeNewswire May 2, 2024

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

GlobeNewswire April 30, 2024

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

GlobeNewswire April 23, 2024

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

GlobeNewswire April 11, 2024

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

GlobeNewswire March 28, 2024

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

GlobeNewswire March 21, 2024

Daré Bioscience to Present at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting

GlobeNewswire February 22, 2024

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

GlobeNewswire January 31, 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

GlobeNewswire January 26, 2024

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

GlobeNewswire January 17, 2024

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

GlobeNewswire January 4, 2024